App-Quantinova.ai

Oncogenic signaling by MET and other cabozantinib targets in cells derived from urothelial carcinoma of the bladder

Young H. Lee - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

ENDOCRINE TOXICITY

F. Roila - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Male Sexual Dysfunction

Cabozantinib

COMBINING CYTOTOXIC CHEMOTHERAPY WITH ANTIANGIOGENIC AGENTS AND COMPLETE RESPONSES IN CANCER PATIENTS: A META ANALYSIS OF PUBLISHED TRIALS

Y. Li - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma: A Potential Therapeutic Target

Levent Ozsari - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adrenal carcinoma

Cabozantinib

Effect of Cabozantinib on Body Composition in Advanced Thyroid Cancer

Lily J Kwatampora - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Cabozantinib

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).

Daniel Olson - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).

Meredith M. Regan - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phaseIII randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.

Nizar M. Tannir - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

PDIGREE: An adaptive phase 3 trialof PD-inhibitor nivolumab andipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreatedrenal cell cancer(Alliance A031704).

Tian Zhang - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.

Robin Kate Kelley - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Prognostic value of sequential18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi).

Nicholas Peter Verdini - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phaseII trial 1317 CaboGIST.

Patrick Schoffski - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phaseIII CELESTIAL trial.

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.

Marcia S. Brose - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.

Matthias Kroiss - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cost-effectiveness of pazopanib as first-line treatment of metastatic renal cell carcinoma from National Health Service United Kingdom perspective.

Barbara Elizabeth Ratto - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Preclinical development of combination therapy targeting the dominant cytokine interleukin-1 for renal cell carcinoma.

David Henry Aggen - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

The Combined Use of Ultrasound and 99mTc Scan in the Evaluation of Tyrosine Kinase Inhibitor-Induced Subacute Thyroiditis with Severe Thyrotoxicosis

Andrea B Apolo - Endocrine Society (ENDO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

Sorafenib induces rapid control of ectopic ACTH syndrome in a patient with metastatic medullary thyroid cancer

Joao Evangelista Bezerra-Neto - Endocrine Society (ENDO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hypothyroidism

Cabozantinib

Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations

KM Hirshfield - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cabozantinib

Filters

366 Abstracts